Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) announced the peer-reviewed publication of Phase 1 clinical data for PF614-MPAR, an oxycodone prodrug using MPAR® technology that limits oral overdose while preserving therapeutic opioid exposure.

Findings show appropriate plasma levels at normal dosing and prevention of large opioid increases at supratherapeutic doses; MPAR received FDA Breakthrough designation in January 2024 and IP extends through 2042.

Positive

• Phase 1 publication validates MPAR® overdose-limiting mechanism in humans
• FDA Breakthrough Therapy designation in January 2024
• Intellectual property protection extending through 2042
• Study supported by National Institute on Drug Abuse funding

Negative

• Clinical program remains early-stage: only Phase 1 data reported

News Market Reaction – ENSC

-15.00%

17 alerts

-15.00% News Effect

-9.6% Trough in 11 hr 25 min

-$375K Valuation Impact

$2M Market Cap

0.1x Rel. Volume

On the day this news was published, ENSC declined 15.00%, reflecting a significant negative market reaction. Argus tracked a trough of -9.6% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $375K from the company's valuation, bringing the market cap to $2M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Phase: Phase 1 Opioid overdose deaths: 80,000 per year Prescription opioid share: 12.4% +5 more

8 metrics

Phase Phase 1 PF614-MPAR clinical study published

Opioid overdose deaths 80,000 per year CDC data cited for annual opioid overdose deaths

Prescription opioid share 12.4% Portion of opioid overdose deaths involving prescription opioids

Daily overdose deaths 30 deaths per day Daily deaths attributed to prescription opioid overdoses

Breakthrough designation date January 2024 MPAR technology received FDA Breakthrough Therapy Designation

IP protection horizon Through 2042 Intellectual property portfolio protection for MPAR technology

Journal issue date Jan/Feb 2026 Journal of Opioid Management issue for PF614-MPAR paper

NIH award number DA047682 National Institute on Drug Abuse grant supporting MPAR research

Market Reality Check

Price: $0.5100 Vol: Volume 6,785,950 vs 20-da...

low vol

$0.5100 Last Close

Volume Volume 6,785,950 vs 20-day average 17,154,500 (relative volume 0.4) indicates muted trading interest ahead of this news. low

Technical Shares at $0.60 are trading below the 200-day MA of $1.78 and remain 89.51% under the 52-week high.

Peers on Argus

ENSC fell 3.72% while peers were mixed: SILO rose 9.35% in sector data but appea...

1 Up 1 Down

ENSC fell 3.72% while peers were mixed: SILO rose 9.35% in sector data but appeared down 13.21% in momentum scans, and other peers like ARTL and TTNP were modestly negative. With only one peer moving down in momentum data, ENSC’s move appears stock-specific rather than a broad biotech rotation.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Strategic review	Neutral	+1.1%	Board initiated strategic alternatives review to explore value-enhancing transactions.
Feb 23	Conference participation	Positive	-6.6%	Announced presentations at four 2026 scientific and industry events on key programs.
Jan 28	Clinical enrollment	Positive	-6.9%	Reported 50% enrollment of subjects for interim review in pivotal PF614 Phase 3 trial.
Jan 21	Patent allowance	Positive	-2.2%	Brazilian patent allowance expanding TAAP and MPAR opioid portfolio protection.
Jan 08	Patent allowance	Positive	-0.9%	EU patent allowance for PF8026 ADHD prodrug with abuse and overdose protection.

Pattern Detected

Recent IP and clinical updates often saw negative price reactions, suggesting a pattern of selling into positive development news.

Recent Company History

Over the past months, Ensysce highlighted multiple milestones, including a Phase 3 enrollment update for PF614 on Jan 28, 2026, new opioid and ADHD-related patents on Jan 8 and Jan 21, 2026, and a strategic alternatives review announced on Feb 25, 2026. Despite generally constructive clinical and IP developments, several of these events coincided with negative price reactions, framing today’s positive Phase 1 publication within a history of market skepticism.

Market Pulse Summary

The stock dropped -15.0% in the session following this news. A negative reaction despite clinically ...

Analysis

The stock dropped -15.0% in the session following this news. A negative reaction despite clinically supportive Phase 1 data fits a pattern where prior positive IP and trial updates were followed by price declines. The company trades around $0.60, far below its $5.72 52-week high, and operates as a small-cap clinical-stage biotech. Investors evaluating the selloff may weigh the long development path against the significance of peer-reviewed validation and existing FDA Breakthrough Therapy Designation.

Key Terms

phase 1, prodrug, plasma levels, breakthrough therapy designation, +4 more

8 terms

phase 1 medical

"Phase 1 Data Published in Journal of Opioid Management"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

prodrug medical

"PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection"

A prodrug is an inactive or less-active compound that is designed to be converted into an active drug inside the body, like a packaged meal that needs heating before it's ready to eat. For investors, prodrugs matter because this design can improve how a medicine is absorbed, reduce side effects, extend patent protection, or enable new dosing forms — all factors that can affect a drug's regulatory path, marketability, and commercial value.

plasma levels medical

"achieved appropriate opioid plasma levels under normal dosing conditions"

Plasma levels are the concentration of a drug or biological molecule measured in the liquid portion of the blood. Investors watch these numbers because they indicate how much of a drug reaches the body, how long it stays at effective doses, and whether levels are safe; like measuring fuel in a tank to judge how far a car can go, plasma levels help predict dosing, side effects, regulatory approval chances, and commercial potential.

breakthrough therapy designation regulatory

"MPARae previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

opioid analgesia medical

"support the potential for a fundamentally new safety paradigm in opioid analgesia"

Opioid analgesia is pain relief achieved by drugs that act on the nervous system to reduce the sensation of pain, comparable to turning down a volume knob on pain signals. For investors, it matters because products that provide opioid analgesia can drive significant sales in pain management but also carry regulatory scrutiny, addiction and liability risks, and reimbursement challenges that can affect a drug maker’s revenue and stock value.

attention-deficit/hyperactivity disorder (adhd) medical

"including amphetamines and methadone-with the goal of developing safer treatments for pain, attention-deficit/hyperactivity disorder (ADHD)"

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition characterized by persistent difficulties with attention, impulsivity and sometimes excessive activity, affecting how people focus, plan and follow through on tasks. It matters to investors because diagnosis rates, treatment choices, workplace accommodations and ongoing research drive demand for medications, digital therapies and specialty services, similar to how changing consumer needs reshape markets and company revenues.

opioid use disorder medical

"and methadone-with the goal of developing safer treatments for pain, attention-deficit/hyperactivity disorder (ADHD), and opioid use disorder"

Opioid use disorder is a medical condition where a person repeatedly seeks and uses opioid drugs despite harmful physical, social or mental effects, often involving strong cravings and withdrawal symptoms when stopping. It matters to investors because its prevalence, availability of effective treatments, regulatory responses, and legal or insurance costs can shift demand, revenue and risk across drug makers, treatment providers and insurers—like a widespread problem that reshapes an entire market.

national institute on drug abuse medical

"The continued support from the National Institute on Drug Abuse2 helped enable this study"

A U.S. federal research agency that studies drug use, addiction, prevention and treatment and funds scientific work in those areas. Its studies, funding choices and public guidance can shape which therapies, diagnostics or public-health programs get developed and adopted—so investors watch it like a traffic signal that can speed up or slow down markets in pharmaceuticals, biotech and healthcare services depending on research findings or funding priorities.

AI-generated analysis. Not financial advice.

~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~

SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the publication of the first clinical manuscript describing its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology.

The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appears online in the Journal of Opioid Management Jan/Feb 2026 issue.

https://wmpllc.org/ojs/index.php/jom/article/view/3977

PF614-MPAR is the first opioid candidate specifically designed to provide active protection against oral overdose-a limitation not addressed by currently marketed abuse-deterrent formulations. MPAR® technology is engineered to maintain therapeutic opioid exposure when taken as prescribed while automatically limiting additional opioid release when excessive numbers of pills are consumed.

Data presented in the publication demonstrate that PF614-MPAR achieved appropriate opioid plasma levels under normal dosing conditions, while preventing large increases in opioid delivery when supratherapeutic doses were administered. These findings support the potential for a fundamentally new safety paradigm in opioid analgesia. MPAR® previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) in January 2024 based on this clinical evidence and the technology is protected by a growing intellectual property portfolio extending through 2042.

"This peer-reviewed publication marks a defining milestone not only for Ensysce, but for the field of pain medicine," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce. "CDC data projects that almost 80,000 people die every year from opioid overdose of which prescription opioids factor into 12.4% of these deaths¹. These numbers, which amount to 30 deaths per day, are still considered a major health crisis. Importantly, to combat against overdose, MPAR® introduces a new class of chemically programmed opioids designed to protect patients even when dosing errors or misuse occur."

The clinical work reported in this publication allowed for the optimization of the MPAR® formulation and the confirmation that the overdose-limiting mechanism functions as intended in humans. The continued support from the National Institute on Drug Abuse² helped enable this study and the ongoing second clinical trial evaluating the MPAR® technology.

Beyond opioid analgesics, Ensysce is advancing MPAR® across additional therapeutic categories-including amphetamines and methadone-with the goal of developing safer treatments for pain, attention-deficit/hyperactivity disorder (ADHD), and opioid use disorder.

^{¹ https://drugabusestatistics.org/opioid-epidemic/}

^{2 Research supporting this patent was funded by the National Institute on Drug Abuse of the National Institutes of Health under Award Number DA047682.}

About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.

Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences

View the original press release on ACCESS Newswire

FAQ

What did Ensysce announce about PF614-MPAR on March 3, 2026 (ENSC)?

Ensysce announced a peer-reviewed Phase 1 publication showing PF614-MPAR limits oral overdose while preserving therapeutic exposure. According to Ensysce, the Journal of Opioid Management paper reports appropriate opioid plasma levels at normal dosing and prevention of large increases at supratherapeutic doses.

How does the MPAR® technology in PF614-MPAR protect against oral opioid overdose (ENSC)?

MPAR® is engineered to maintain therapeutic opioid release but limit additional opioid delivery when pills are overconsumed. According to Ensysce, the Phase 1 data show the mechanism prevents large increases in opioid delivery at supratherapeutic doses in humans.

What regulatory recognition has Ensysce received for MPAR® technology (ENSC)?

MPAR® received FDA Breakthrough Therapy designation in January 2024, signaling expedited review potential. According to Ensysce, this designation was granted based on clinical evidence supporting the overdose-limiting mechanism.

What is the current clinical status and next steps for PF614-MPAR (ENSC)?

PF614-MPAR has completed Phase 1 and an ongoing second clinical trial is underway. According to Ensysce, the Phase 1 publication enabled formulation optimization and confirmed the overdose-limiting mechanism in humans.

Does Ensysce have patent protection for MPAR® and how long does it extend (ENSC)?

Ensysce reports a growing intellectual property portfolio protecting MPAR® technology with coverage through 2042. According to Ensysce, the portfolio secures the platform as it advances into additional therapeutic categories.